New depression drug SP-101 enters first human safety trial
NCT ID NCT07334249
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial is the first time SP-101 is being tested in humans. It will enroll 80 healthy adults to check the drug's safety, tolerability, and how the body processes it. SP-101 works by blocking NMDA receptors in the brain, a different approach from standard antidepressants. The study does not yet test if the drug works for depression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SP-101 (a drug that blocks NMDA receptors in the brain)
- What this could lead to
- If successful, this could lead to a new treatment option for major depressive disorder, especially for people who don't respond to current antidepressants.
- What could go wrong
- This is a very early Phase 1 trial in healthy volunteers, not patients. It only tests safety and dosing, not whether SP-101 actually helps depression. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER, HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Mental Health Center (SMHC)
Shanghai, Shanghai Municipality, 200030, China